AI Article Synopsis

  • During pregnancy, increased coagulation factor levels create a "physiological" hypercoagulability, beneficial for preventing hemorrhage during delivery but raising the risk of venous thrombosis.
  • Antithrombin, a key inhibitor of coagulation, can become deficient due to various conditions, leading to increased thrombosis risk, either acquired or inherited.
  • The study discusses the case of a pregnant woman with deep vein thrombosis and antithrombin deficiency while examining the potential benefits of routine antithrombin testing and supplementation, especially for obese women, highlighting the lack of established guidelines for treatment.

Article Abstract

During pregnancy the concentrations of many coagulation factors are increased what leads to a "physiological" hypercoagulability status and constitutes a natural protection against delivery hemorrhage. These changes may be conducive to venous thrombembolism. Antithrombin is one of the endogenous clotting inhibitors. As a serine protease, it inactivates thrombin and the efficiency of this reaction is intensified by heparin. Acquired antithrombin deficiency is caused by disseminated intravascular coagulation syndrome, deep vein thrombosis, neoplasms, nephritic syndrome, renal failure, liver diseases, long-term estrogen treatment, dialysis or extracorporeal circulation. There are also cases of inherited antithrombin deficiency which leads to thrombophilia. The following study presents a course of pregnancy and postpartum of a woman with deep vein thrombosis and acquired antithrombin deficiency as well as the applied treatment. The legitimacy of routine assay of antithrombin activity and antithrombin supplementation in pregnant women with thrombosis was considered. This procedure may be helpful when dealing with obese pregnant patients as it is difficulty to identify and establish a therapeutic dose of heparin in their cases. Therapy guidelines for pregnant patients with thrombosis and acquired antithrombin deficiency have not been established yet.

Download full-text PDF

Source

Publication Analysis

Top Keywords

antithrombin deficiency
16
acquired antithrombin
12
antithrombin
9
venous thrombembolism
8
routine assay
8
assay antithrombin
8
antithrombin activity
8
activity antithrombin
8
deep vein
8
vein thrombosis
8

Similar Publications

In the pursuit of personalized medicine, there is a growing demand for computational models with parameters that are easily obtainable to accelerate the development of potential solutions. Blood tests, owing to their affordability, accessibility, and routine use in healthcare, offer valuable biomarkers for assessing hemostatic balance in thrombotic and bleeding disorders. Incorporating these biomarkers into computational models of blood coagulation is crucial for creating patient-specific models, which allow for the analysis of the influence of these biomarkers on clot formation.

View Article and Find Full Text PDF

A new hereditary PROS1 gene mutation caused isolated cortical venous thrombosis.

Thromb Res

January 2025

Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. Electronic address:

Background: Protein S deficiency is a rare inherited disease. We report the case of a young man who unexpectedly developed isolated cortical vein thrombosis (ICoVT) associated with a novel PROS1 mutation.

Methods: Clinical symptoms were recorded, and physical examinations conducted.

View Article and Find Full Text PDF

Antithrombin III deficiency and idiopathic intracranial hypertension: a case report.

J Med Case Rep

January 2025

Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.

Background: Idiopathic intracranial hypertension (IIH) is a condition where the pressure of the cerebrospinal fluid in the brain increases without a known cause. It typically affects adults but can also occur in adolescents and children, although it is less common. Numerous elements, including coagulopathy, have been documented in previous cases as potential etiological factors of IIH.

View Article and Find Full Text PDF

Advances in biopharmaceutical products for hemophilia.

iScience

December 2024

Chengdu Rongsheng Pharmaceuticals Co., Ltd, Chengdu 610041, China.

Hemophilia is caused by the deficiency of clotting factors due to a single genetic abnormality. Replacement therapies have evolved from plasma-derived to recombinant coagulation factor concentrates but continue to have certain limitations. Monoclonal antibodies are clinical prophylactic treatment options unaffected by inhibitors and have better compliance than coagulation factor concentrates for patients with hemophilia.

View Article and Find Full Text PDF

Clinical and functional characterization of p.Lys322stop variant in the SERPINC1 gene causing severe thrombophilia.

Orphanet J Rare Dis

December 2024

Thrombosis Research Center, Beijing Jishuitan Hospital, Capital Medical University, Xicheng District, Beijing, 100035, China.

Background: Identification of mutations in the SERPINC1 has illuminated the intricate pathways underlying antithrombin (AT) deficiency. Our group identified a variation in the SERPINC1 gene (c.964 A > T, p.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!